MedTrace Logo

Dynamic Monitoring of ctDNA and HPV DNA in Plasma for the Early Prediction of Recurrence After Cervical Cancer Surgery

NCT06420427 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2024-05-20

No results posted yet for this study

Summary

Assess the sensitivity, specificity, positive predictive value, and negative predictive value of dynamic monitoring of circulating tumor DNA (ctDNA) combined with circulating HPV DNA (cfHPV DNA) for early prediction of recurrence in cervical cancer post-surgery or post-treatment, and compare its advantages and disadvantages with existing diagnostic methods.

Conditions

  • cfHPV DNA in Plasma of Cervical Cancer Patients

Interventions

DIAGNOSTIC_TEST

Assess the risk of recurrence and the efficacy of medication

Evaluation of recurrence risk and medication efficacy through liquid biopsy

Sponsors & Collaborators

  • The Third Affiliated Hospital of Guangzhou Medical University

    lead OTHER

Principal Investigators

  • Xiujie Sheng, Prof · The Third Affiliated Hospital of Guangzhou Medical University

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2025-12-31
Completion
2027-01-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06420427 on ClinicalTrials.gov